OSR Holdings heads into its May 20 earnings with the most dramatic two-week unwind in borrow activity seen all year — and the stock is up 24% on the week as a result.
The standout story this week is not where short interest sits today but where it has been. Estimated short interest peaked above 9% of free float on May 5, having quadrupled from under 2% in barely five sessions. That spike coincided with borrow costs blowing through 100% annualised on May 5 — the highest point in the 30-day window — and availability collapsing to just 7%. At those levels, new short positions were extremely expensive to establish. Since then, shorts have been cut roughly in half to 4.2% of the float, borrow costs have retreated to 43%, and availability has loosened to 75%. The borrow market is still materially tighter than it was in April, when availability ran above 400% and costs hovered near 21%, but the acute squeeze pressure has clearly eased.
The unwinding is happening in parallel with the price rally. OSRH closed at $0.64, up 13% on Tuesday and 24% on the week, suggesting the rapid short-covering contributed to the move. The ORTEX short score — a composite measure of short-side pressure — confirms the shift: it peaked at 80.6 on May 5 and has dropped to 71.2 as of Tuesday, a meaningful step-down even if the reading remains elevated. Days-to-cover ranks in the 77th percentile, which flags the position as relatively sticky when trading volume is thin, as is common for a micro-cap biotech trading below $1.
Ownership remains highly concentrated, which adds an important dimension to the positioning picture. Bellevue Capital Management holds around 33% of shares, and a single named individual, Kuk Hwang, accounts for another 20%. A newer entrant, joint protein central inc., disclosed a 7.9% stake as recently as April. Together, those three parties account for roughly 62% of shares outstanding. In a float this small, even modest institutional flows can move availability rapidly — which likely explains why the borrow market swings so violently from one fortnight to the next.
The analyst picture offers little directional signal. The sole rating on record is a hold, last filed in late March and now more than six weeks stale. There are no recent target price changes to group or assess. On valuation, the enterprise value is cited near $69 million as of year-end 2025, but with no current market cap provided and the stock trading well below $1, that figure deserves caution as a point of comparison.
With Q1 earnings scheduled for May 20, the earnings history suggests limited directional conviction: the last four prints produced next-day moves of -2%, +11%, -14%, and flat — a scatter pattern rather than a trend. The combination of elevated borrow costs, a 24% weekly price surge, and an imminent catalyst is the setup worth watching into next week.
See the live data behind this article on ORTEX.
Open OSRH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
